221 related articles for article (PubMed ID: 37277696)
21. Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma.
Kruthika BS; Sugur H; Nandaki K; Arimappamagan A; Paturu K; Santosh V
J Clin Pathol; 2019 Oct; 72(10):677-681. PubMed ID: 31270134
[TBL] [Abstract][Full Text] [Related]
22. PBK as a Potential Biomarker Associated with Prognosis of Glioblastoma.
Dong C; Fan W; Fang S
J Mol Neurosci; 2020 Jan; 70(1):56-64. PubMed ID: 31617063
[TBL] [Abstract][Full Text] [Related]
23. Integrated bioinformatics analyses identifying potential biomarkers for type 2 diabetes mellitus and breast cancer: In SIK1-ness and health.
Durrani IA; Bhatti A; John P
PLoS One; 2023; 18(8):e0289839. PubMed ID: 37556419
[TBL] [Abstract][Full Text] [Related]
24. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
25. Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology.
ElBanan MG; Amer AM; Zinn PO; Colen RR
Neuroimaging Clin N Am; 2015 Feb; 25(1):141-53. PubMed ID: 25476518
[TBL] [Abstract][Full Text] [Related]
26. Applications of emerging molecular technologies in glioblastoma multiforme.
Kumar HR; Zhong X; Sandoval JA; Hickey RJ; Malkas LH
Expert Rev Neurother; 2008 Oct; 8(10):1497-506. PubMed ID: 18928343
[TBL] [Abstract][Full Text] [Related]
27. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
[TBL] [Abstract][Full Text] [Related]
28. Computational analysis and verification of molecular genetic targets for glioblastoma.
Xue L; Liu H; Chen Y; Wei L; Hong J
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32469390
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel prognostic targets in glioblastoma using bioinformatics analysis.
Yin X; Wu Q; Hao Z; Chen L
Biomed Eng Online; 2022 Apr; 21(1):26. PubMed ID: 35436915
[TBL] [Abstract][Full Text] [Related]
30. SLC12A5 as a novel potential biomarker of glioblastoma multiforme.
Chen J; Wang H; Deng C; Fei M
Mol Biol Rep; 2023 May; 50(5):4285-4299. PubMed ID: 36917367
[TBL] [Abstract][Full Text] [Related]
31. Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme.
Kabir F; Apu MNH
Genomics; 2022 May; 114(3):110378. PubMed ID: 35513291
[TBL] [Abstract][Full Text] [Related]
32. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
33. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
[TBL] [Abstract][Full Text] [Related]
34. Screening prognosis-related genes in glioblastoma by microarray analysis.
Wang H; Zhang Y; Zhang C; Tong X
Anticancer Drugs; 2020 Feb; 31(2):150-157. PubMed ID: 31567312
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes.
Gulluoglu S; Tuysuz EC; Sahin M; Kuskucu A; Kaan Yaltirik C; Ture U; Kucukkaraduman B; Akbar MW; Gure AO; Bayrak OF; Dalan AB
Brain Res; 2018 Dec; 1700():199-210. PubMed ID: 30176243
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
Li H; Wang D; Yi B; Cai H; Xi Z; Lou X; Li Z
Biomed Res Int; 2021; 2021():8357585. PubMed ID: 34395626
[TBL] [Abstract][Full Text] [Related]
37. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract][Full Text] [Related]
38. Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis.
Wei B; Wang L; Du C; Hu G; Wang L; Jin Y; Kong D
Mol Med Rep; 2015 Apr; 11(4):2548-54. PubMed ID: 25514975
[TBL] [Abstract][Full Text] [Related]
39. Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms.
Trépant AL; Bouchart C; Rorive S; Sauvage S; Decaestecker C; Demetter P; Salmon I
Tumour Biol; 2015 Mar; 36(3):1943-53. PubMed ID: 25384509
[TBL] [Abstract][Full Text] [Related]
40. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
Cho HJ; Zhao J; Jung SW; Ladewig E; Kong DS; Suh YL; Lee Y; Kim D; Ahn SH; Bordyuh M; Kang HJ; Sa JK; Seo YJ; Kim ST; Lim DH; Dho YS; Lee JI; Seol HJ; Choi JW; Park WY; Park CK; Rabadan R; Nam DH
Neuro Oncol; 2019 Jan; 21(1):47-58. PubMed ID: 30085274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
